期刊
MATURITAS
卷 75, 期 4, 页码 392-396出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.maturitas.2013.05.013
关键词
Osteoporosis; Fracture; FRAX; Guideline
资金
- Servier
- Consilient Health
- Amgen/GSK
- Shire
- Eli Lilly
- Amgen
- GSK
- MSD
- Novartis
- Proctor Gamble
- ProStrakan
- Roche
- Medtronic
- Tethys
- GE Lunar
- Bayer
- Hologic
- Lilly
- Merck
- Pfizer
- Warner-Chilcott
- Innovus 3i
- Alliance for Better Bone Health
- Biointetica
- Celtrix
- D3A
- General Electric
- Kissel
- Medimaps
- Merck Research Labs
- Sanofi-Aventis
- UBS
- Olympus
- Synthes
- Stryker
- Biomet
- Medical Research Council [MR/K006312/1] Funding Source: researchfish
- MRC [MR/K006312/1] Funding Source: UKRI
Since the launch in 2008 by the National Osteoporosis Guideline Group (NOGG), of guidance for the diagnosis and management of osteoporosis in postmenopausal women and older men in the UK there have been significant advances in risk assessment and treatment. These have been incorporated into an updated version of the guideline, with an additional focus on the management of glucocorticoid-induced osteoporosis, the role of calcium and vitamin D therapy and the benefits and risks of long-term bisphosphonate therapy. The updated guideline is summarised below. The recommendations in the guideline are intended to aid management decisions but do not replace the need for clinical judgement in the care of individuals in clinical practice. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据